RxDoctor Payments DataLook up a doctor →

Bethany Sleckman, MD

Medical Oncology · Saint Louis, MONPI 1861814386

Payments from drug & device makers

$2,434,372in general payments, 2019–2025

Across 1,562 payments — averaging $1558.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.3M
  • Pfizer$614K
  • Genentech, Inc.$164K
  • Novartis$71K
  • Pharmacyclics LLC, An Abbvie Company$59K
  • Bristol Myers Squibb$49K
  • plus $178K from 54 others
$7,010in research payments, 2019–2025

Across 7 payments — averaging $1001.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$7K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck350$1,299,031
Pfizer404$614,303
Genentech, Inc.24$164,126
Novartis43$71,266
Pharmacyclics LLC, An Abbvie Company30$58,740
Bristol Myers Squibb53$49,003
AbbVie34$30,567
GSK15$27,678
Exelixis Inc.14$23,155
Incyte Corporation22$22,081
AstraZeneca47$18,981
Macrogenics, Inc.6$13,888
Radius Health, Inc.5$13,500
Eli Lilly4$12,380
E.r. Squibb & Sons, L.L.C.40$5,230
Daiichi Sankyo Inc.76$1,675
Johnson & Johnson(2 entities)59$1,285
Genentech USA, Inc.25$743
Seagen Inc.27$590
Sanofi25$543
EMD Serono, Inc.29$523
Gilead(2 entities)25$434
Amgen20$420
Regeneron Healthcare Solutions, Inc.10$351
Tempus AI, Inc6$277
Eisai Inc.11$262
Boehringer Ingelheim12$216
Takeda Pharmaceuticals U.S.A., Inc.11$208
Beigene USA, Inc.8$178
Lilly USA, LLC10$174
Bayer8$169
Gen-probe, Inc.1$150
Beone Medicines USA, Inc.5$134
Medtronic1$122
Tersera Therapeutics LLC4$120
Karyopharm Therapeutics Inc.5$115
Taiho Oncology, Inc.7$113
Rigel Pharmaceuticals, Inc.6$103
Jazz Pharmaceuticals Inc.4$99
Array Biopharma Inc6$97
GT Medical Technologies, Inc3$90
Kyowa Kirin, Inc.5$84
Mylan Institutional Inc.4$81
Astellas Pharma US Inc4$73
Sumitomo Pharma America, Inc.3$66
Stemline Therapeutics Inc.3$64
AVEO Pharmaceuticals, Inc.4$61
Servier Pharmaceuticals LLC3$55
Mirati Therapeutics, Inc.3$55
ADC Therapeutics America, Inc.2$49
Verastem, Inc.3$49
Pharmaessentia USA Corporation2$45
Agios Pharmaceuticals, Inc.2$37
Morphosys, US Inc.2$36
Genmab U.S., Inc.2$32
Ipsen Biopharmaceuticals, Inc2$32
Myovant Sciences Inc.2$31
Myriad Genetic Laboratories, Inc.1$30
Adaptive Biotechnologies Corporation1$27
Novocure Inc.1$25

How this compares

$2,434,372 in reported general payments places this provider in the 80th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri →

Medicare billing

Part B allowed, 2024
$64,001
Medicare patients
367
Services billed
823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →